Emerging treatments

Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma. Mikhael JR et al. Br J Haematol. 2015 Feb 13. doi: 10.1111/bjh.13296. [Epub ahead of print]. Everolimus (RAD001) Activity in Relapsed and/or Refractory Multiple Myeloma: A Phase I Study. Guenther A et al. Haematologica. 2015 Feb 14. pii: haematol.2014.116269. [Epub ahead of print]. Phase I/II Study of the Combination…

Biology and genetics

Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cells. Anastasiadou E et al. Int J Cancer. 2015 Feb 20. doi: 10.1002/ijc.29489. [Epub ahead of print]. BCL2L11/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance. Dai Y et al. Autophagy. 2015 Feb 20:0. [Epub ahead of print]. Hyaluronan synthase 1: a mysterious enzyme with unexpected functions. Siiskonen H et…

Supportive care

OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Holtick U et al. Eur J Haematol. 2015 Feb 23. doi: 10.1111/ejh.12541. [Epub ahead of print]. Use of allogeneic platelet gel in the management of chemotherapy extravasation injuries: a case report. Di Costanzo G et al. Onco…

General

The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence. Hostenkamp G et al. Soc Sci Med. 2015 Feb 7;130C:162-171. doi: 10.1016/j.socscimed.2015.02.003. [Epub ahead of print]. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease. Ashjian E et al. J Oncol Pharm Pract. 2015 Feb 17. pii: 1078155215572036. [Epub ahead of print]. Advance…

Complications of myeloma and its treatments

Management of tumor lysis syndrome in patients with multiple myeloma during bortezomib treatment. Wang L et al. Clin J Oncol Nurs. 2015 Feb 1;19(1):E4-7. doi: 10.1188/15.CJON.E4-E7. Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib. Peng L et al. Support Care Cancer. 2015 Feb 13. [Epub ahead of print]. Renal insufficiency retains adverse prognostic implications despite renal function improvement following…

Diagnostic tests and prognostic indicators

18F-FDG PET/CT, 99mTc-MIBI, and MRI in the Prediction of Outcome of Patients With Multiple Myeloma: A Comparative Study. Fonti R et al. Clin Nucl Med. 2015 Jan 20. [Epub ahead of print]. Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement. Dimopoulos MA et al. J Clin Oncol. 2015 Jan 20. pii: JCO.2014.57.9961. [Epub…

Emerging treatments

Multiple Myeloma Yields to CD38 Inhibitors. [No authors listed]. Cancer Discov. 2015 Jan 16. [Epub ahead of print]. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Atrash S et al. Blood Cancer J. 2015 Jan 16;5:e272. doi: 10.1038/bcj.2014.93. Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant. Mangiacavalli S et al. Leuk…

Biology and genetics

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02. Leleu X et al. Blood. 2015 Jan 9. pii: blood-2014-11-612069. [Epub ahead of print]. The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution. Puig N et al. Leukemia. 2015 Jan 8. doi: 10.1038/leu.2015.7. [Epub ahead of print]. Combined immune checkpoint protein blockade…